$BDSX

SCHULER JACK W purchased $666K of BDSX (indirect holdings)

SCHULER JACK W purchased 27,600 indirectly-held shares of BIODESIX INC (BDSX) at an average of $24.13 ($24.01–$24.25, $0.67M total) across 2 trades over 2026-08-10 to 2026-08-11.

Original reporting
SEC EDGAR · SCHULER JACK W
Published Aug 12, 2026, 9:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BDSX
Neutral
low confidence
Mentioned
$BDSX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDSXNeutralLow
01

Why it matters

The only new fact is the insider purchase size, price range, and post-transaction share count; there is no accompanying guidance, trial result, contract, or regulatory update.

02

Market read

Traders may note the insider buy as a mild sentiment input, but it does not change the fundamental information set from this text alone.

03

What to watch

The filing does not disclose the economic rationale, whether the purchase is funded by pre-existing arrangements, or whether other insiders are acting similarly.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-12 after trades on 2026-08-10 to 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for BIODESIX, filed on 2026-08-12, covering purchases made 2026-08-10 to 2026-08-11.

Company-level read

Ticker impact

$BDSXNeutralLow confidence
Context

SEC Form 4 shows 10% owner Schuler Jack W bought 27,600 shares of BIODESIX (indirect) for about $665,940 at $24.01 to $24.25.

Expected impact

Likely limited near-term impact; any effect would be small and short-lived unless followed by additional disclosures.

Evidence & confidence

Form 4 insider purchases can be read as bullish, but the filing provides no new operating or financial information, and indirect holdings reduce interpretability.

Market effects

No sector-level signal; this is company-specific insider activity without new clinical, regulatory, or commercial details.

None indicated.

None indicated.

Counterpoint

Indirect holdings and lack of a 10b5-1 plan do not necessarily imply a strong forward view; it could reflect liquidity, estate, or rebalancing mechanics.

Key entities

  • BIODESIX

    Company whose shares were purchased; Form 4 lists the insider as a 10% owner with indirect holdings.

  • SCHULER JACK W

    10% owner reporting an open-market purchase of 27,600 shares across two trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BDSXMedAI 8/10

Biodesix (BDSX) Q2 2026 Earnings Call Transcript

Biodesix (BDSX) reported Q2 2026 results and discussed clinical demand drivers for its Nodify lung nodule biomarkers. The company said March publication of a lung nodule validation study increased Nodify CDT orders for nodules as small as 4 mm. Q2 revenue rose 34% to $26.9M, diagnostic testing revenue $25.4M (+42%), gross margin 82%, and net loss was $7.3M. Full-year revenue outlook remains $108M to $114M.

$BDSXHigh

BIODESIX INC (BDSX): Results of Operations and Financial Condition

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Confere